Page 2 - Daniel Janney News Today

Krystal Biotech (NASDAQ:KRYS – Get Rating) had its price target boosted by HC Wainwright from $119.00 to $139.00 in a report released on Monday, The Fly reports. HC Wainwright also issued estimates for Krystal Biotech’s Q3 2023 earnings at ($1.02) EPS, Q4 2023 earnings at ($0.93) EPS, FY2023 earnings at ($4.90) EPS, FY2024 earnings at […]

Krystal Biotech (NASDAQ:KRYS – Get Rating) had its price target increased by Chardan Capital from $133.00 to $148.00 in a research report sent to investors on Monday morning, The Fly reports. Chardan Capital also issued estimates for Krystal Biotech’s FY2023 earnings at ($5.46) EPS and FY2024 earnings at $3.03 EPS. A number of other research […]

Krystal Biotech (NASDAQ:KRYS – Get Rating) had its price target raised by equities research analysts at Stifel Nicolaus from $102.00 to $145.00 in a report issued on Wednesday, The Fly reports. Stifel Nicolaus’ price objective suggests a potential upside of 23.52% from the stock’s current price. Other equities analysts have also recently issued reports about […]

Krystal Biotech (NASDAQ:KRYS – Get Rating) had its target price hoisted by Guggenheim from $101.00 to $130.00 in a research report released on Monday morning, The Fly reports. Other equities analysts also recently issued reports about the stock. Chardan Capital boosted their price target on shares of Krystal Biotech from $133.00 to $148.00 in a […]

Citigroup Inc. cut its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Get Rating) by 42.3% in the 4th quarter, Holdings Channel reports. The institutional investor owned 28,760 shares of the company’s stock after selling 21,063 shares during the quarter. Citigroup Inc.’s holdings in Krystal Biotech were worth $2,278,000 at the end of the […]

Krystal Biotech (NASDAQ:KRYS – Get Rating) had its target price upped by Chardan Capital from $133.00 to $148.00 in a research note issued to investors on Monday morning, The Fly reports. Other equities analysts have also recently issued research reports about the stock. William Blair reaffirmed an outperform rating on shares of Krystal Biotech in […]

Krystal Biotech (NASDAQ:KRYS – Get Rating) had its target price boosted by Guggenheim from $101.00 to $130.00 in a report issued on Monday, The Fly reports. Guggenheim’s price target indicates a potential upside of 9.12% from the stock’s current price. Other equities analysts also recently issued research reports about the stock. Stifel Nicolaus began coverage […]

Krystal Biotech, Inc. (NASDAQ:KRYS – Get Rating) Director Daniel Janney sold 50,000 shares of Krystal Biotech stock in a transaction on Friday, May 19th. The stock was sold at an average price of $95.02, for a total transaction of $4,751,000.00. Following the sale, the director now directly owns 157,362 shares in the company, valued at […]

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Get Rating) have earned a consensus rating of “Buy” from the six brokerages that are presently covering the company, MarketBeat reports. Six investment analysts have rated the stock with a buy rating. The average 1-year price objective among analysts that have issued ratings on the stock in the […]

Krystal Biotech, Inc. (NASDAQ:KRYS – Get Rating)’s stock price reached a new 52-week high during trading on Friday . The company traded as high as $94.61 and last traded at $93.64, with a volume of 774086 shares. The stock had previously closed at $87.45. Analyst Ratings Changes A number of equities research analysts have issued […]